Avant Technologies Advances Cell-in-a-Box Technology for Immunosuppression-Free Diabetes Therapy at EPITA Symposium
核心洞察
Avant Technologies (搜索) is evaluating advanced cells for diabetes therapy using its Cell-in-a-Box (搜索)® microencapsulation technology at the 15th European Pancreas and Islet Transplantation Association Symposium.
The company's clinically proven platform offers a safe alternative to traditional immunosuppression by protecting transplanted insulin-producing cells from immune rejection without associated risks.
Dr. Eva Maria Lilli Brandtner highlighted that while stem cell-derived beta cells represent a breakthrough in unlimited insulin sources, immune protection remains a key challenge that their technology addresses effectively.
Avant Technologies (搜索), Inc. (OTCQB: AVAI) is actively evaluating advanced cells for potential diabetes therapy applications at the 15th European Pancreas and Islet Transplantation Association (EPITA (搜索)) Symposium, held January 25-27, 2026, in Igls, Austria. The emerging biotechnology company is showcasing its Cell-in-a-Box (搜索)® microencapsulation technology as a promising solution to address immune rejection challenges in cell-based diabetes treatments.
Cell-in-a-Box Technology Addresses Key Clinical Challenge
Dr. Eva Maria Lilli Brandtner, Avant Technologies (搜索)' expert representative at the symposium, is assessing promising cells for inclusion with the company's Cell-in-a-Box (搜索)® technology, developed in partnership with SGAustria (搜索). This clinically proven microencapsulation platform offers a safe, side-effect-free alternative to traditional immunosuppression methods.
"While stem cell-derived beta cells undoubtedly represent a breakthrough in unlimited insulin sources, immune protection still remains a key challenge," said Dr. Brandtner. "Avant's Cell-in-a-Box (搜索)® technology addresses this effectively, positioning us to contribute meaningfully to beta cell replacement therapies for type 1 and insulin-dependent type 2 diabetes patients worldwide."
The technology protects transplanted insulin-producing cells from immune rejection without the potential risks associated with gene editing and immunosuppression, such as tumor formation or infections.
Strategic Partnership and Platform Development
Avant Technologies (搜索) has developed its microencapsulation platform through a partnership with SGAustria (搜索) Pte. Ltd., a Singapore-based biotechnology company specializing in clinically proven cell encapsulation and GMP-grade cell products. SGAustria brings significant scientific credibility to the collaboration, backed by over 50 peer-reviewed publications and partnerships with global biotech companies.
The Cell-in-a-Box (搜索)® technology represents a significant advancement in addressing one of the primary obstacles in cell-based diabetes therapy: protecting transplanted cells from immune system attack while maintaining their therapeutic function.
EPITA Symposium Platform
The EPITA (搜索) Symposium serves as one of the world's flagship associations for advancing biological therapies for diabetes, including islet transplantation and beta cell replacement. The event brings together global scientists, clinicians, and industry leaders to foster collaboration and accelerate the development of therapies for widespread clinical application.
Avant Technologies (搜索)' participation in this premier European event underscores the company's commitment to strengthening its role in the diabetes therapy community and highlighting its innovative approach to enabling scalable, patient-friendly cell therapies.
Company Focus and Development Strategy
As an emerging biotechnology company, Avant Technologies (搜索) focuses on identifying genetically modified cell lines and developing innovative cell-based therapies through joint venture and licensing agreements. The company's approach emphasizes developing treatments for diabetes and age-related disorders, positioning itself as a leader in immunosuppression-free cell therapy solutions.
The company's strategy centers on creating therapies that can be widely accessible to patients while avoiding the complications and risks associated with traditional immunosuppressive treatments required for cell transplantation procedures.